biOasis collaborates with NRC on blood-brain barrier agent
biOasis Technologies has commenced a sponsored research agreement with the National Research Council (NRC) of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.
The Vancouver, British Columbia-based biOasis is developing a proprietary carrier called Transcend for the transport of therapeutic and imaging agents across the blood-brain barrier.
"The agreement with the NRC will provide the company with demonstration of the ability of Transcend to carry a fluorescent dye that is normally excluded from the brain, across the blood-brain barrier. This will enable its visualization and localization in brain tissue and further add to our understanding of the potential for Transcend to deliver therapeutic agents into the brain,” said CEO Rob Hutchison.
The Vancouver, British Columbia-based biOasis is developing a proprietary carrier called Transcend for the transport of therapeutic and imaging agents across the blood-brain barrier.
"The agreement with the NRC will provide the company with demonstration of the ability of Transcend to carry a fluorescent dye that is normally excluded from the brain, across the blood-brain barrier. This will enable its visualization and localization in brain tissue and further add to our understanding of the potential for Transcend to deliver therapeutic agents into the brain,” said CEO Rob Hutchison.